What investors can see in Exact Sciences today

Exact Sciences (EXAS) continues to attract attention as a cancer diagnostics business with US$3,246.99m in annual revenue, a reported net loss of US$207.949m, and a recent share price around US$103.50.

At around US$103.50, Exact Sciences has seen relatively steady short term share price moves, while the 1 year total shareholder return of 117.30% contrasts with a 5 year total shareholder return decline of 18.60%. This suggests that momentum has been more recent rather than long standing.

If cancer diagnostics has your attention, it could be a good moment to broaden your watchlist and check out 31 healthcare AI stocks as a fresh set of ideas in a related space.

With Exact Sciences reporting revenue of US$3,246.99m, a net loss of US$207.949m, a 117.30% 1-year return and an estimated 31% intrinsic discount, is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 2.2% Undervalued

Exact Sciences' most followed narrative pegs fair value at about $105.81 per share, slightly above the recent $103.50 price, which frames a tight valuation gap.

Multi-year operational cost optimization initiatives (targeting $150M in annual savings by 2026 via automation, AI-driven lab/process efficiencies, and reduced G&A spend) are establishing a foundation for expanding EBITDA and net margins over time, especially as scale effects take hold.

Curious what has to happen for that fair value to hold up? The narrative leans on faster revenue compounding, margin lift, and a richer future earnings multiple. The exact mix may surprise you.

Result: Fair Value of $105.81 (UNDERVALUED)

However, the story could shift if Cologuard's concentration becomes a weak spot, or if blood based screening and MCED tests see slower adoption or reimbursement progress.

Next Steps

If this narrative feels optimistic or cautious to you, do not sit on the sidelines. Pull up the numbers, pressure test the assumptions, and weigh 4 key rewards against your own expectations.

Looking for more investment ideas?

If Exact Sciences is on your radar, do not stop there. Cast the net wider with a few focused screens that can surface opportunities you might otherwise miss.

• Target potential value opportunities by checking out 47 high quality undervalued stocks that currently combine stronger fundamentals with what our models flag as mispriced.
• Prioritize resilience and sleep a bit easier at night by reviewing 77 resilient stocks with low risk scores that score well on our risk checks.
• Get ahead of the crowd by scouting screener containing 24 high quality undiscovered gems that our filters highlight but many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.